[
    [
        {
            "time": "2020-07-31",
            "original_text": "贝达药业二季业绩下滑严重，年内多次减持 | 中报季 减持股份数",
            "features": {
                "keywords": [
                    "贝达药业",
                    "二季业绩",
                    "下滑",
                    "减持"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业二季业绩下滑严重，年内多次减持 | 中报季 减持股份数",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-05",
            "original_text": "贝达药业(300558.SZ)：将在区域内启动Balsilimab和Zalifrelimab相关的临床研究",
            "features": {
                "keywords": [
                    "贝达药业",
                    "临床研究",
                    "Balsilimab",
                    "Zalifrelimab"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：将在区域内启动Balsilimab和Zalifrelimab相关的临床研究",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-08-10",
            "original_text": "贝达药业(300558.SZ)：股东济和创投解除质押1400万股",
            "features": {
                "keywords": [
                    "贝达药业",
                    "股东",
                    "解除质押",
                    "1400万股"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "资本运作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业(300558.SZ)：股东济和创投解除质押1400万股",
                "Correlation": 8,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 7,
                "Headline_Structure": 5,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-15",
            "original_text": "贝达药业(300558)：业绩符合预期 研发与商务合作均有突破",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩",
                    "研发",
                    "商务合作",
                    "突破"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "研发",
                    "合作"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩符合预期 研发与商务合作均有突破",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-08-20",
            "original_text": "贝达药业(300558)：业绩整体表现良好 恩沙替尼即将获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "业绩",
                    "恩沙替尼",
                    "即将获批"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "新药审批"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558)：业绩整体表现良好 恩沙替尼即将获批",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2020-08-25",
            "original_text": "贝达药业(300558)2020年中报点评：上半年埃克替尼业绩亮眼 下半年恩沙替尼有望获批",
            "features": {
                "keywords": [
                    "贝达药业",
                    "中报",
                    "埃克替尼",
                    "恩沙替尼",
                    "有望获批"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "研发",
                    "新药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558)2020年中报点评：上半年埃克替尼业绩亮眼 下半年恩沙替尼有望获批",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 4
            }
        },
        {
            "time": "2020-08-30",
            "original_text": "[面包财报] 贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
            "features": {
                "keywords": [
                    "贝达药业",
                    "第二季度",
                    "归母净利润",
                    "下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "财务"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "[面包财报] 贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-05",
            "original_text": "贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
            "features": {
                "keywords": [
                    "贝达药业",
                    "第二季度",
                    "归母净利润",
                    "下降",
                    "盈利能力"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "财务"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "贝达药业：第二季度归母净利润1332.52万元，同比下降62.61% 盈利能力下降",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2020-09-10",
            "original_text": "贝达药业(300558)：埃克替尼持续稳定增长 研发即将进入收获期",
            "features": {
                "keywords": [
                    "贝达药业",
                    "埃克替尼",
                    "稳定增长",
                    "研发",
                    "收获期"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "研发"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "贝达药业(300558)：埃克替尼持续稳定增长 研发即将进入收获期",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 6
            }
        },
        {
            "time": "2020-09-15",
            "original_text": "贝达药业公布半年报 上半年净利增加64.65%",
            "features": {
                "keywords": [
                    "贝达药业",
                    "半年报",
                    "净利",
                    "增加"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药",
                    "财务"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "贝达药业公布半年报 上半年净利增加64.65%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        }
    ]
]